Skip to main content

Pilot and Feasibility Program - PKD Center

New RFAs posted on  2/8/2019:

The Kansas PKD Research and Translation Core Center will offer three P&F grants funded through the P30 grant, plus two additional, targeted P&F grants funded by institutional matching dollars. Offering five P&F grants per year, locally and nationally, will maximize the development of research related to the Core Center theme and will accelerate the growth of the Biomedical Research Cores and the training of new PKD physician-scientists. The P&F grants being offered by the Kansas PKD Core Center are:

  1. Ten P30 Pilot & Feasibility grants have been awarded through July 2018 to internal and external investigators with a focus on the Kansas Core Center theme "Target identification for PKD therapy development."

          Status: Three pilot projects were awarded on 9/15/2015 through June 2017:

    1. "Does the O-GlcNAc post-translational modification regulate the development of PKD and can it be used as an early-stage biomarker for PKD?
      PI: Chad Slawson, Ph.D.
      Assistant Professor to the Department of Biochemistry and Molecular Biology
      University of Kansas Medical Center

    2. "Potential role of the NLRP3 inflammasome in the cystic progression of PKD"
      PI: Katherine Swenson-Fields, Ph.D.
      University of Kansas Medical Center

    3. "Role of the Hippo kinase pathway in hepatic cyst growth and pericystic fibrosis in autosomal recessive polycystic kidney disease"
      PI: Michele Pritchard, Ph.D.
      Assistant Professor in the Department of Pharmacology, Toxicology and Therapeutics
      University of Kansas Medical Center

      Status: An additional pilot grant was awarded in 2016 through 2018:

    4.  "Regulations of M2-pyruvate Kinase control of Warburg Metabolism of Polycystic Kidney Disease and Cancer."
      PI:
      Aron Fenton, Ph.D.

      Status: Three more pilot projects were awarded in July 2017 through June 2019:

    5. "Assessment of longitudinal changes in endothelial function and oxidative stress in normotensive patients with ADPKD"
      PI: Maria Irazabal Mira, M.D. - Mayo Clinic

    6. "Role of Osteopontin in Polycystic Kidney Disease Progression"
      PI: Jason Stubbs, M.D., - University of Kansas Medical Center

    7. "Mechanisms Partitioning Polycystin Localization and Function between Cilia and Extracellular Vesicles (EVs)"
      PI: Juan Wang, PhD, Rutgers University

  2. One Department of Internal Medicine/Kidney Institute P&F grant for $50k in directs per year that will be focused on clinically oriented PKD translational research by junior faculty in any of the medicine subspecialties.

    Status:
    In 2016, Reena Rao, Ph.D., was awarded this pilot grant for her project titled, "Vasopressin Signaling: A Common Pathogenic Process in Polycystic Kidney Disease and Renal Cell Carcinoma"

    In 2018, Kerri McGreal, MD was awarded this pilot grant for her project titled, "Biomarker Discovery and Dose-Finding Study of Hydralazine in ADPKD Patients" 

  3. One KU Cancer Center Pilot & Feasibility grant for $50k in directs per year (internal) on the relationship between PKD and cancer to take advantage of rapid advances in targeted therapy development in the cancer field.

    Status
    : In 2016, Jeremy Chien, Ph.D., was awarded this pilot grant for his project titled, "FoxM1 Pathway in Polycystic Kidney Disease"

    In 2017 and 2018, Reena Rao, Ph.D., was awarded this pilot grant for her project titled, "Vasopressin Signaling: A Common Pathogenic Process in Polycystic Kidney Disease and Renal Cell Carcinoma"

Last modified: Feb 14, 2019
ID=x25775